Novartis launches interactive Retina App

Article

Novartis has launched a fully interactive Facebook app, ?Retina App,? which simulates retinal disease by illustrating the user?s journey with a highly realistic view of the possible impact of vision loss on their daily lives.

Basel, Switzerland-To raise awareness of retinal disease, Novartis has launched a fully interactive Facebook app, “Retina App” on World Sight Day October 10, 2013. The app, part of the “Set Your Sights” campaign, simulates retinal disease by illustrating the user’s journey with a highly realistic view of the possible impact of vision loss on their daily lives.

The app is geared to encourage patients with retinal diseases, such as wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and choroidal neovascularization secondary to pathologic myopia, to engage with vision loss and experience what it means to live with a sight-diminishing condition. Users of the app will be presented with a fully tailored, through-the-lens view of their own photos and friends video experience that is a highly realistic view of what their life with retinal disease could be like.

The “Set Your Sights” campaign was mounted in response to the “2020 Vision Report” from the World Health Organization that concluded that nearly 80% of global blindness is preventable if managed correctly.

“As the global leader in the field of retinal disease, Novartis is proud to support World Sight Day by creating further dialogue among people living with low-vision conditions and the wider community, generating an environment of understanding and tolerance,” said David Epstein, head of the pharmaceuticals division, Novartis Pharma AG. “This is an important initiative in the pharmaceutical environment, reflecting our focus to always put the patient first.”

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.